Suppr超能文献

基于结构的鉴定和中和机制的酪氨酸硫酸盐类似物,抑制 HIV-1 进入。

Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.

机构信息

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

出版信息

ACS Chem Biol. 2011 Oct 21;6(10):1069-77. doi: 10.1021/cb200068b. Epub 2011 Aug 5.

Abstract

Tyrosine sulfate-mediated interactions play an important role in HIV-1 entry. After engaging the CD4 receptor at the cell surface, the HIV-1 gp120 glycoprotein binds to the CCR5 co-receptor via an interaction that requires two tyrosine sulfates, at positions 10 and 14 in the CCR5-N terminus. Building on previous structure determinations of this interaction, here we report the targeting of these tyrosine sulfate binding sites for drug design through in silico screening of small molecule libraries, identification of lead compounds, and characterization of biological activity. A class of tyrosine sulfate-mimicking small molecules containing a "phenyl sulfonate-linker-aromatic" motif was identified that specifically inhibited binding of gp120 to the CCR5-N terminus as well as to sulfated antibodies that recognize the co-receptor binding region on gp120. The most potent of these compounds bound gp120 with low micromolar affinity and its CD4-induced conformation with K(D)'s as tight as ∼50 nM. Neutralization experiments suggested the targeted site to be conformationally inaccessible prior to CD4 engagement. Primary HIV-1 isolates were weakly neutralized, preincubation with soluble CD4 enhanced neutralization, and engineered isolates with increased dependence on the N terminus of CCR5 or with reduced conformational barriers were neutralized with IC(50) values as low as ∼1 μM. These results reveal the potential of targeting the tyrosine sulfate interactions of HIV-1 and provide insight into how mechanistic barriers, evolved by HIV-1 to evade antibody recognition, also restrict small-molecule-mediated neutralization.

摘要

酪氨酸硫酸盐介导的相互作用在 HIV-1 进入中发挥着重要作用。在细胞表面与 CD4 受体结合后,HIV-1 gp120 糖蛋白通过需要 CCR5 N 末端两个酪氨酸硫酸盐(位置 10 和 14)的相互作用与 CCR5 共受体结合。基于之前对该相互作用的结构测定,我们通过对小分子文库进行计算机筛选、鉴定先导化合物和表征生物活性,报告了靶向这些酪氨酸硫酸盐结合位点的药物设计。鉴定出了一类含有“苯磺酸盐 - 连接子 - 芳基”基序的酪氨酸硫酸盐模拟小分子,它们特异性抑制 gp120 与 CCR5 N 末端的结合以及与识别 gp120 共受体结合区的硫酸化抗体的结合。这些化合物中最有效的一种以低微摩尔亲和力与 gp120 结合,其 CD4 诱导构象的 K(D)'值与约 50 nM 一样紧密。中和实验表明,在与 CD4 结合之前,靶向位点的构象不可接近。原始 HIV-1 分离株的中和作用较弱,可溶性 CD4 的预孵育增强了中和作用,并且依赖 CCR5 N 末端的工程改造分离株或构象障碍降低的分离株的中和作用的 IC(50)值低至约 1 μM。这些结果揭示了靶向 HIV-1 酪氨酸硫酸盐相互作用的潜力,并提供了有关 HIV-1 逃避抗体识别的机制障碍如何也限制小分子介导的中和作用的见解。

相似文献

引用本文的文献

9
Molecular mechanism of respiratory syncytial virus fusion inhibitors.呼吸道合胞病毒融合抑制剂的分子机制
Nat Chem Biol. 2016 Feb;12(2):87-93. doi: 10.1038/nchembio.1982. Epub 2015 Dec 7.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验